These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 35859328

  • 1. PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: A multicenter, prospective, randomized study.
    Sun XS, Wang Z, Ren SH, Zhang HL, Liu LJ, Du HB, Liu XW, Liu JF.
    Thorac Cancer; 2022 Sep; 13(17):2429-2435. PubMed ID: 35859328
    [Abstract] [Full Text] [Related]

  • 2. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK, He XH, Yang S, Wang HQ, Jiang ZF, Zhu YZ, Ke XY, Zhang Y, Liu YP, Zhang WJ, Wang Z, Shi QZ, Xie XD, Zhang HL, Wang JJ, Luo DY, Zheng QS, Sun RY.
    Zhonghua Yi Xue Za Zhi; 2006 Dec 26; 86(48):3414-9. PubMed ID: 17313855
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Application of pegylated recombinant human granulocyte colony-stimulating factor to prevent chemotherapy-induced neutropenia in patients with lymphoma: a prospective, multicenter, open-label clinical trial].
    Huang HQ, Bai B, Gao YH, Zou DH, Zou SH, Tan H, Song YP, Li ZY, Jin J, Li W, Su H, Gong YP, Zhong MZ, Shuang YR, Zhu J, Zhang JQ, Cai Z, Teng QL, Sun WJ, Yang Y, Xia ZJ, Chen HL, Hua LM, Bao YY, Wu N.
    Zhonghua Xue Ye Xue Za Zhi; 2017 Oct 14; 38(10):825-830. PubMed ID: 29166732
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
    Ji X, Xu L, Pan P, Xu Z, Wang A, Li Y.
    Thorac Cancer; 2022 Jan 14; 13(1):117-125. PubMed ID: 34791805
    [Abstract] [Full Text] [Related]

  • 6. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
    Xie J, Cao J, Wang JF, Zhang BH, Zeng XH, Zheng H, Zhang Y, Cai L, Wu YD, Yao Q, Zhao XC, Mao WD, Jiang AM, Chen SS, Yang SE, Wang SS, Wang JH, Pan YY, Ren BY, Chen YJ, Ouyang LZ, Lei KJ, Gao JH, Huang WH, Huang Z, Shou T, He YL, Cheng J, Sun Y, Li WM, Cui SD, Wang X, Rao ZG, Ma H, Liu W, Wu XY, Shen WX, Cao FL, Xiao ZM, Wu B, Tian SY, Meng D, Shen P, Wang BY, Wang Z, Zhang J, Wang L, Hu XC.
    Breast Cancer Res Treat; 2018 Apr 14; 168(2):389-399. PubMed ID: 29230663
    [Abstract] [Full Text] [Related]

  • 7. A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF).
    Huang X, Li S, Shi W, Wang Y, Wan X, He J, Xu Y, Zhang W, Shi X, Chen R, Xu L, Zha X, Wang J.
    Br J Clin Pharmacol; 2023 Jan 14; 89(1):372-379. PubMed ID: 36001055
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
    Jiang Y, Zhang J, Zhong J, Liao H, Zhang J, Liu Y, Liang Y, Li H.
    BMC Cancer; 2023 Jul 26; 23(1):702. PubMed ID: 37495949
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer.
    Zou D, Guo M, Zhou Q.
    BMC Cancer; 2021 Jun 02; 21(1):661. PubMed ID: 34078317
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S, Shi YK, Liu P, Han XH, He XH, Cai YM, Chen ZM.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun 02; 28(3):339-44. PubMed ID: 16900629
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
    Huang W, Liu J, Zeng Y, Wu F, Li N, Chen K, Hong Y, Wang L, Zhen H, Lin L.
    Cancer Chemother Pharmacol; 2018 Oct 02; 82(4):607-613. PubMed ID: 30043207
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study.
    Liu C, Hao Y, Wang L, Meng F, Wen F, Zhong D.
    Thorac Cancer; 2021 Apr 02; 12(8):1154-1161. PubMed ID: 33590721
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.